Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Replicate Studies Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients With Primary Biliary Cholangitis

Next Previous
Trial Profile

Replicate Studies Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients With Primary Biliary Cholangitis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obeticholic acid (Primary) ; Ursodeoxycholic acid
  • Indications Primary biliary cirrhosis
  • Focus Therapeutic Use
  • Acronyms HEROES PBC
  • Sponsors Intercept Pharmaceuticals

Most Recent Events

  • 10 Nov 2022 According to an Intercept Pharmaceuticals media release, results from this study were presented at the American Association for the Study of Liver Diseases (AASLD) last week.
  • 08 Nov 2022 Results assessing the effect of OCA treatment on time to the first occurrence of thecomposite endpoint of all-cause death, liver transplant,or hospitalization for hepatic decompensation, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
  • 30 Jul 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top